Trials / Completed
CompletedNCT00994292
Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in Combination With Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects With Acute Coronary Syndromes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,276 (actual)
- Sponsor
- Astellas Pharma Europe B.V. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of various doses of YM150 (the experimental drug) in the prevention of ischemic vascular events in subjects with recent acute coronary syndromes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM150 | oral |
| DRUG | Placebo | oral |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-02-01
- Completion
- 2011-03-01
- First posted
- 2009-10-14
- Last updated
- 2015-10-19
Locations
131 sites across 21 countries: Argentina, Australia, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, France, Germany, Hungary, India, Mexico, Netherlands, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Ukraine
Source: ClinicalTrials.gov record NCT00994292. Inclusion in this directory is not an endorsement.